Default apoptotic programs have been adapted as a first line of defense against cancer, and virtually all cancer cells have mutations that activate """"""""survival signals"""""""" in order to suppress apoptosis. A central node in survival signaling is mTOR (the mammalian target of rapamycin). mTOR is activated in response to signals mediated by the phosphatidylinositol-3-kinase (PI3K) signaling pathway. However, more recently it has become apparent that mTOR is also targeted by signals that activate phospholipase D (PLD). PLD generates phosphatidic acid (PA), a lipid second messenger that interacts directly with mTOR in a manner that is competitive with rapamycin - and PA is required for the activation of mTOR. Importantly, PLD activity is elevated in several types of human cancer. PLD activity is elevated in many human cancer cells and is required for mTOR-mediated signals that are critical for survival and promote cell cycle progression. The CENTRAL HYPOTHESIS of the proposal is - Elevated PLD activity in human cancer cells promotes passage through a late G1 """"""""Cell Growth Checkpoint"""""""" and suppresses default apoptotic programs. We are proposing that virtually all cancer cells must activate signals that allow passage through this checkpoint. SPECIFICALLY, we propose: 1) To determine how PLD-mTOR signaling impacts on cell cycle progression through a proposed Cell Growth Checkpoint;2) To determine the mechanism by which PLD-generated PA regulates mTORC1 and mTORC2 in concert with other signaling inputs;and 3) To characterize signals that lead to elevated PLD activity in human cancer cell lines and to evaluate targeting these signals pharmacologically both in vitro and in vivo. We are proposing that a PLD-mTOR signaling pathway in human cancer cells represents a widely employed strategy by cancer cells to promote cell cycle progression and suppress default apoptotic programs. The studies proposed here will provide a framework for the rational targeting of an apparent large number of cancers that depend upon elevated PLD activity for G1 cell cycle progression and suppression of apoptosis.

Public Health Relevance

The proposed study will evaluate the intracellular mechanisms that regulate phospholipase D (PLD) and mTOR in human cancer cells and the impact of these signals on a proposed Cell Growth Checkpoint in the G1 phase of the cell cycle that we are proposing must be overcome in virtually all human cancers. The project builds on our previous findings that there is elevated phospholipase D (PLD) activity in many human cancer cells and that suppression of PLD activity in these cells results in apoptotic cell death. Targeting the PLD-mTOR signals in cancer cells represents a very promising strategy for resurrecting the default cell death programs that are arguably the first line of defense against cancer - and is therefore a fertile area for translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA046677-20S2
Application #
8787891
Study Section
Program Officer
Spalholz, Barbara A
Project Start
1989-08-25
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2015-02-28
Support Year
20
Fiscal Year
2014
Total Cost
$60,850
Indirect Cost
$21,079
Name
Hunter College
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
620127915
City
New York
State
NY
Country
United States
Zip Code
10065
Mukhopadhyay, Suman; Frias, Maria A; Chatterjee, Amrita et al. (2016) The Enigma of Rapamycin Dosage. Mol Cancer Ther 15:347-53
Patel, Deven; Menon, Deepak; Bernfeld, Elyssa et al. (2016) Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells. J Biol Chem 291:9322-9
Saqcena, Mahesh; Patel, Deven; Menon, Deepak et al. (2015) Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. Cell Cycle 14:2285-92
Mukhopadhyay, Suman; Chatterjee, Amrita; Kogan, Diane et al. (2015) 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle 14:3331-9
Chatterjee, Amrita; Mukhopadhyay, Suman; Tung, Kaity et al. (2015) Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways. Cancer Lett 360:134-40
Mukhopadhyay, Suman; Saqcena, Mahesh; Chatterjee, Amrita et al. (2015) Reciprocal regulation of AMP-activated protein kinase and phospholipase D. J Biol Chem 290:6986-93
LeGendre, Onica; Breslin, Paul As; Foster, David A (2015) (-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. Mol Cell Oncol 2:e1006077
Saqcena, M; Mukhopadhyay, S; Hosny, C et al. (2015) Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 34:2672-80
Yellen, Paige; Foster, David A (2014) Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells. Cancer Lett 353:258-63
Salloum, Darin; Mukhopadhyay, Suman; Tung, Kaity et al. (2014) Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther 13:733-41

Showing the most recent 10 out of 28 publications